18.2 C
New York
Monday, June 17, 2024

Galectin Therapeutics Pops 50% on U.S. Patent

Courtesy of Benzinga.

Gevo, Inc. (NASDAQ: GEVO) issues statement regarding U.S. Patent and Trademark Office (USPTO) announcement to grant the Butamax(TM) Advanced Biofuels, LLC (Butamax) Request for Reexamination of Gevo’s (http://www.gevo.com/our-business/our-science-and-technology/) GIFT® technology, U.S. Patent 8,101,808.

“Reexaminations are part of the normal course of a (http://www.gevo.com/our-business/intellectual-property/) patent dispute, especially when dealing with valuable technology. This reexamination does not validate patent applications of Butamax or anyone else — that isn’t what reexaminations do. The headline in the Butamax press release is inflammatory and misleading.

Gevo’s ‘808 Patent covers multiple production technologies for higher alcohols in retrofitted ethanol plants. We believe that Butamax is infringing at least one of those technologies. While our claims have been set aside in this most recent USPTO action, Gevo’s lawsuit against Butamax for infringing this ‘808 Patent remains unaffected; the trial is scheduled for July of 2014.

Subscribe
Notify of
0 Comments
Inline Feedbacks
View all comments

Stay Connected

157,081FansLike
396,312FollowersFollow
2,300SubscribersSubscribe

Latest Articles

0
Would love your thoughts, please comment.x
()
x